SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001493152-22-035788
Filing Date
2022-12-16
Accepted
2022-12-16 17:24:55
Documents
16
Period of Report
2022-12-12
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-ka.htm   iXBRL 8-K/A 187790
2 ex99-4.htm EX-99.4 110909
3 ex99-5.htm EX-99.5 277466
4 ex99-6.htm EX-99.6 169346
  Complete submission text file 0001493152-22-035788.txt   1033765

Data Files

Seq Description Document Type Size
5 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zvsa-20221212.xsd EX-101.SCH 3462
6 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT zvsa-20221212_def.xml EX-101.DEF 26188
7 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zvsa-20221212_lab.xml EX-101.LAB 35952
8 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zvsa-20221212_pre.xml EX-101.PRE 24846
10 EXTRACTED XBRL INSTANCE DOCUMENT form8-ka_htm.xml XML 5262
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

IRS No.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-41184 | Film No.: 221468976
SIC: 2834 Pharmaceutical Preparations